Effect | Decrease |
Trial Design | Double blind |
Trial Length | 2-4 Weeks |
Number of Subjects | 82 |
Sex | Both Genders |
Age Range | 18-29, 30-44, 45-64 |
Body Types | Average |
In adults with generalized anxiety disorder, supplementation of 240-480mg EGb-761 daily for 4 weeks is associated with less anxiety symptoms as assessed by the HAMA rating scale. The amount of persons reaching a 50% reduction in symptoms was 22% in placebo and 39-44% with EGb-761 with the higher dose being slightly more effective.
Symptoms appeared to be significantly reduced by the end of the trial, but there were no significant differences at the half-way point of 2 weeks.